AstraZeneca PLC (LON:AZN) Receives £121.57 Average Target Price from Analysts

Shares of AstraZeneca PLC (LON:AZN) have received a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is £121.57 ($154.47).

Several research firms have commented on AZN. Berenberg Bank lifted their target price on shares of AstraZeneca from £130 ($165.18) to £150 ($190.60) and gave the stock a “buy” rating in a research report on Friday, June 7th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, June 4th. Jefferies Financial Group reiterated a “hold” rating and set a £113 ($143.58) price objective on shares of AstraZeneca in a research report on Tuesday, May 21st. Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a report on Tuesday, May 21st. Finally, Citigroup reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Tuesday, May 28th.

AstraZeneca Price Performance

Shares of LON AZN opened at £124.72 ($158.48) on Wednesday. The company has a debt-to-equity ratio of 92.51, a quick ratio of 0.59 and a current ratio of 0.89. The stock has a market cap of £193.32 billion, a price-to-earnings ratio of 3,997.44, a PEG ratio of 0.97 and a beta of 0.16. The firm’s 50-day simple moving average is £120.78 and its 200 day simple moving average is £109.88. AstraZeneca has a fifty-two week low of GBX 9,461 ($120.22) and a fifty-two week high of £127.04 ($161.42).

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.